Autonomix Medical, Inc. (AMIX)
| Market Cap | 3.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.72M |
| Shares Out | 543.30K |
| EPS (ttm) | -48.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,150 |
| Open | 5.76 |
| Previous Close | 5.72 |
| Day's Range | 5.72 - 5.99 |
| 52-Week Range | 4.20 - 55.44 |
| Beta | -1.41 |
| Analysts | Buy |
| Price Target | 58.80 (+906.85%) |
| Earnings Date | Aug 12, 2026 |
About AMIX
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders of nervous system. The company’s technology platform includes a catheter-based system incorporating microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Med... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for AMIX stock is "Buy." The 12-month stock price target is $58.8, which is an increase of 906.85% from the latest price.
News
Autonomix Medical Inc trading halted, news pending
19:50 EDT Autonomix (AMIX) Medical Inc trading halted, news pending
Autonomix develops standalone neural sensing platform
Autonomix (AMIX) announced the development of a proprietary standalone neural sensing platform following preclinical results showing evidence of the ability to identify renal neural activity and detec...
Autonomix develops standalone neural sensing platform
Autonomix (AMIX) announced the development of a proprietary standalone neural sensing platform following preclinical results showing evidence of the ability to identify renal neural activity and detec...
Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change
Platform Expected to Target Expansion into Multi-Billion-Dollar Cardiovascular Market with Potential Class II Diagnostic Regulatory Path Architecture Supports Future Expansion into Denervation, includ...
Autonomix announces reverse stock split
Autonomix (AMIX) “announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-21…
Autonomix Announces Reverse Stock Split
THE WOODLANDS, TX, June 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tre...
Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Global Scientific and Clinical Recognition of Platform Technology
Access the segment here THE WOODLANDS, TX, June 10, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing pre...
Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine
Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential
Autonomix Medical Annual report: Q4 2026
Autonomix Medical has published its Q4 2026 annual report on May 27, 2026.
Autonomix granted U.S. patent for transvascular monitoring, treatment systems
Autonomix (AMIX) announced the United States Patent and Trademark Office has issued U.S. Patent No. 12,544,131. The newly granted patent covers catheter-based transvascular tools and systems designed ...
Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation
Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall
Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted trea...
Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
THE WOODLANDS, TX, April 29, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tr...
Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026
THE WOODLANDS, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tr...
Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026
THE WOODLANDS, TX, April 08, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tr...
Autonomix Medical to Present at LSI USA '26
THE WOODLANDS, TX, March 11, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tr...
Autonomix Medical Selected for Best Innovation Competition at CRT 2026
THE WOODLANDS, TX, March 05, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tr...
Autonomix to present clinical study on Nerve Neurolysis at CRT 2026
Autonomix (AMIX) Medical announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies, CRT, 2026 Meeting, happening March 7-10, ...
Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis
THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tr...
Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation
CEO, Brad Hauser, discusses building clinical credibility through rigorous science and peer-reviewed engagement THE WOODLANDS, TX, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AM...
Autonomix selected to present new long-term pain mitigation data at SSO 2026
Autonomix (AMIX) Medical announced that Clarke Wilkirson, PhD, Clinical Development Engineer II, will present new long-term clinical data at the Society of Surgical Oncology, SSO, 2026 Annual Meeting,...
Autonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation
THE WOODLANDS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tre...
Autonomix price target lowered to $2 from $5 at Maxim
Maxim lowered the firm’s price target on Autonomix (AMIX) to $2 from $5 and keeps a Buy rating on the shares. The company’s Q3 results were slightly better than expected,…
Autonomix Medical Quarterly report: Q3 2026
Autonomix Medical has published its Q3 2026 quarterly earnings report on February 11, 2026.
Autonomix announces final clinical data on pain mitigation in pancreatic cancer
Autonomix (AMIX) Medical announced that final clinical data evaluating its transvascular radiofrequency ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the Soci...